NeuroPace (NPCE) Cash from Investing Activities Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Cash from Investing Activities Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | 17.83% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | -6.23% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | -32.54% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -68.12% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 37.39% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | -11.04% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 19.58% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | -17.67% |
| 10 | NeuroPace | 470.30 Mn | 418.60 Mn | 18.91 Mn | -26.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.49% |
| Mar 31, 2026 | -26.24% |
| Dec 31, 2025 | -26.22% |
| Sep 30, 2025 | -26.08% |
| Jun 30, 2025 | -26.42% |
| Mar 31, 2025 | 50.55% |
| Dec 31, 2024 | 145.15% |
| Sep 30, 2024 | 110.81% |
| Jun 30, 2024 | 26.84% |
| Mar 31, 2024 | 35.28% |
| Dec 31, 2023 | 32.86% |
| Sep 30, 2023 | 165.73% |
| Mar 31, 2023 | 185.93% |